Skip to main content
Erschienen in: Supportive Care in Cancer 12/2012

01.12.2012 | Original Article

Oral health is an important issue in end-of-life cancer care

verfasst von: Petter Wilberg, Marianne J. Hjermstad, Stig Ottesen, Bente B. Herlofson

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to assess the prevalence of oral morbidity in patients receiving palliative care for cancers outside the head and neck region and to investigate if information concerning oral problems was given.

Methods

Patients were recruited from two Norwegian palliative care inpatient units. All patients went through a face-to-face interview, completed the Edmonton Symptom Assessment System (ESAS) covering 10 frequent cancer-related symptoms, and went through an oral examination including a mouth swab to test for Candida carriage.

Results

Ninety-nine of 126 patients (79 %) agreed to participate. The examined patients had a mean age of 64 years (range, 36–90 years) and 47 % were male. Median Karnofsky score was 40 (range, 20–80) and 87 % had metastatic disease. Estimated life expectancy was <3 months in 73 %. Dry mouth was reported by 78 %. The highest mean scores on the modified 0–10 ESAS scale were 4.9 (fatigue), 4.7 (dry mouth), and 4.4 (poor appetite). Clinical oral candidiasis was seen in 34 % (86 % positive cultures). Mouth pain was reported by 67 % and problems with food intake were reported by 56 %. Moderate or rich amounts of dental plaque were seen in 24 %, and mean number of teeth with visible carious lesions was 1.9. One patient was diagnosed with bisphosphonate-related osteonecrosis of the jaw. Overall, 78 % said they had received no information about oral adverse effects of cancer treatment.

Conclusion

Patients in palliative care units need better mouth care. Increased awareness among staff about the presence and severity of oral problems is necessary. Systematic information about oral problems is important in all stages of cancer treatment.
Literatur
3.
Zurück zum Zitat von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ (1993) Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119(2):121–126 von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ (1993) Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119(2):121–126
5.
Zurück zum Zitat Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN et al (2010) A systematic review of salivary gland hypofunction induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18:1039–1060. doi:10.1007/s00520-010-0827-8 PubMedCrossRef Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN et al (2010) A systematic review of salivary gland hypofunction induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18:1039–1060. doi:10.​1007/​s00520-010-0827-8 PubMedCrossRef
7.
Zurück zum Zitat Toth BB, Chambers MS, Fleming TJ, Lemon JC, Martin JW (1995) Minimizing oral complications of cancer treatment. Oncology (Williston Park) 9(9):851–858 Toth BB, Chambers MS, Fleming TJ, Lemon JC, Martin JW (1995) Minimizing oral complications of cancer treatment. Oncology (Williston Park) 9(9):851–858
8.
Zurück zum Zitat Toth BB, Chambers MS, Fleming TC (1996) Prevention and management of oral complications associated with cancer therapies: radiotherapy/chemotherapy. Tex Dent J 113(6):23–29PubMed Toth BB, Chambers MS, Fleming TC (1996) Prevention and management of oral complications associated with cancer therapies: radiotherapy/chemotherapy. Tex Dent J 113(6):23–29PubMed
11.
Zurück zum Zitat Öhrn KE, Wahlin YB, Sjoden PO (2001) Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9(4):247–257. doi:10.1007/s005200000214 PubMedCrossRef Öhrn KE, Wahlin YB, Sjoden PO (2001) Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9(4):247–257. doi:10.​1007/​s005200000214 PubMedCrossRef
12.
Zurück zum Zitat Hammerlid E, Mercke C, Sullivan M, Westin T (1997) A prospective quality of life study of patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without brachytherapy. Oral Oncol 33(3):189–196. doi:10.1016/s0964-1955(96)00069-3 PubMedCrossRef Hammerlid E, Mercke C, Sullivan M, Westin T (1997) A prospective quality of life study of patients with oral or pharyngeal carcinoma treated with external beam irradiation with or without brachytherapy. Oral Oncol 33(3):189–196. doi:10.​1016/​s0964-1955(96)00069-3 PubMedCrossRef
17.
19.
Zurück zum Zitat Hong CH, Napeñas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, Spijkervet FK, Brennan MT, Dental Disease Section, Oral Care Study Group, Multi-national Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18(8):1007–1021. doi:10.1007/s00520-010-0873-2 PubMedCrossRef Hong CH, Napeñas JJ, Hodgson BD, Stokman MA, Mathers-Stauffer V, Elting LS, Spijkervet FK, Brennan MT, Dental Disease Section, Oral Care Study Group, Multi-national Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer 18(8):1007–1021. doi:10.​1007/​s00520-010-0873-2 PubMedCrossRef
20.
Zurück zum Zitat Knutson JW (1944) An index of the prevalence of dental caries in schoolchildren. Public Health Rep 59(8):253–263CrossRef Knutson JW (1944) An index of the prevalence of dental caries in schoolchildren. Public Health Rep 59(8):253–263CrossRef
24.
Zurück zum Zitat Migliorati CA, Covington JS 3rd (2009) New oncology drugs and osteonecrosis of the jaw (ONJ). J Tenn Dent Assoc 89(4):36–38PubMed Migliorati CA, Covington JS 3rd (2009) New oncology drugs and osteonecrosis of the jaw (ONJ). J Tenn Dent Assoc 89(4):36–38PubMed
26.
Zurück zum Zitat Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed
28.
Zurück zum Zitat Bergh I, Kvalem IL, Aass N, Hjermstad MJ (2011) What does the answer mean? A qualitative study of how palliative cancer patients interpret and respond to the Edmonton Symptom Assessment System. Palliat Med 25(7):716–724. doi:10.1177/0269216310395985 PubMedCrossRef Bergh I, Kvalem IL, Aass N, Hjermstad MJ (2011) What does the answer mean? A qualitative study of how palliative cancer patients interpret and respond to the Edmonton Symptom Assessment System. Palliat Med 25(7):716–724. doi:10.​1177/​0269216310395985​ PubMedCrossRef
34.
Zurück zum Zitat Worthington HV, Clarkson JE, Khalid T, Meyer S, McCabe M (2010) Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev (7):CD001972. doi:10.1002/14651858.CD001972.pub4 Worthington HV, Clarkson JE, Khalid T, Meyer S, McCabe M (2010) Interventions for preventing oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev (7):CD001972. doi:10.​1002/​14651858.​CD001972.​pub4
Metadaten
Titel
Oral health is an important issue in end-of-life cancer care
verfasst von
Petter Wilberg
Marianne J. Hjermstad
Stig Ottesen
Bente B. Herlofson
Publikationsdatum
01.12.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1441-8

Weitere Artikel der Ausgabe 12/2012

Supportive Care in Cancer 12/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.